Core Viewpoint - China Biopharmaceutical has submitted a new indication application for its CDK2/4/6 inhibitor TQB3616 in combination with Fulvestrant for previously untreated HR+/HER2- locally advanced or metastatic breast cancer to the CDE, which has been accepted [1][2] Group 1: Clinical Research and Development - TQB3616-III-02 (NCT04523272) is a randomized, double-blind, parallel-controlled, multi-center Phase III clinical study aimed at evaluating the efficacy and safety of TQB3616 combined with Fulvestrant compared to placebo plus Fulvestrant in previously untreated HR+/HER2- advanced breast cancer patients [1] - The study has achieved its primary endpoint, with detailed data to be presented at an upcoming international academic conference [1] Group 2: Market Potential and Guidelines - Breast cancer is the most common malignant tumor among women, with HR+/HER2- breast cancer accounting for approximately 65%-70% of all breast cancer cases [1] - About 4%-6% of breast cancer patients are diagnosed at an advanced stage, and even early-stage patients have a 30%-40% chance of progressing to advanced disease despite standard adjuvant therapy [1] - The CSCO Breast Cancer Guidelines (2025 edition) recommend CDK4/6 inhibitors in combination with endocrine therapy for first-line treatment of HR+/HER2- advanced breast cancer [1]

Core Viewpoint - The company has submitted a new indication application for its self-developed CDK2/4/6 inhibitor TQB3616 in combination with Fulvestrant for previously untreated HR-positive, HER2-negative locally advanced or metastatic breast cancer to the National Medical Products Administration of China, which has been accepted [1] Group 1 - The application for the first-line indication further confirms the broad potential of this combination therapy in different treatment stages of advanced breast cancer [1] - The study has achieved its primary endpoint, with detailed data expected to be presented at an upcoming international academic conference [1]

Group 1 - Goldman Sachs adjusts target prices for Chinese pharmaceutical stocks, maintaining "Buy" ratings for China Biologic Products (01177) with a target price raised from HKD 3.92 to HKD 6.19, Hansoh Pharmaceutical (03692) from HKD 22.71 to HKD 34.83, and Innovent Biologics with a target price from HKD 74.95 to HKD 96.22, while upgrading the rating for CStone Pharmaceuticals (02616) from "Neutral" to "Buy" with a target price raised from HKD 2.77 to HKD 6.25 [1] - The report highlights a strong performance in the stock prices of Chinese biotech companies, which have risen 78% year-to-date, compared to 41% and 2% for offshore and onshore healthcare stocks respectively, and 18% for the MSCI China Index, indicating a structural shift rather than a temporary rebound [1][2] Group 2 - The potential for upward growth is further supported by product licensing, mergers and acquisitions, and the establishment of new companies, with China accounting for about one-third of the global clinical trial pipeline by mid-2025 and approximately 50% of innovative drug candidates entering human studies in the first half of the year [2] - Chinese companies are leading in new therapies that may define future standard treatments, particularly in areas such as ADCs (antibody-drug conjugates) and BsAb/TCEs, while also emerging as significant players in siRNA and PROTAC fields [2] - The focus on oncology and obesity is expected to grow, with ADC/BsAb representing a key differentiating advantage for China, accounting for one-third of outbound licensing deals, while siRNA and PROTAC pipelines may present future trading opportunities [2] Group 3 - Goldman Sachs introduces a new "Probability of Licensing Success" (PoLS) framework to assess the potential outbound value of Chinese biotech/pharmaceutical pipelines, suggesting that summer presents an opportunity to accumulate high-quality innovative drug stocks [3] - The firm remains optimistic about leading biotech companies such as BeiGene (06160), Innovent Biologics (01801), and Kelun-Biotech (06990), highlighting their significant upside potential by the second half of 2025 [3] - Specific companies like Innovent Biologics, Zai Lab (09688), and Legend Biotech Corporation (LEGN.US) are noted for their promising data releases and sales growth, indicating strong future performance [3]

Market Overview - On July 9, the Hang Seng Index fell by 1.06%, closing at 23,892.32 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 9.256 billion [1][3] - The total trading volume for the Stock Connect on July 9 was HKD 132.654 billion, with a net purchase of HKD 9.256 billion [1] Stock Performance - In the Shanghai Stock Connect, the total trading volume was HKD 88.533 billion, with a net purchase of HKD 6.585 billion; in the Shenzhen Stock Connect, the trading volume was HKD 44.122 billion, with a net purchase of HKD 2.672 billion [1] - The most actively traded stock in the Shanghai Stock Connect was Legend Holdings, with a trading volume of HKD 10.867 billion, followed by Guotai Junan International and Alibaba-W, with trading volumes of HKD 9.711 billion and HKD 4.349 billion, respectively [1][2] - In terms of net buying, China Construction Bank led with a net purchase of HKD 1.1 billion, despite its stock price declining by 0.24% [1] - Tencent Holdings had the highest net selling amount at HKD 49 million, with its stock price down by 1.37% [1] Shenzhen Stock Connect Highlights - In the Shenzhen Stock Connect, Guotai Junan International topped the trading volume with HKD 3.649 billion, followed by Legend Holdings and Alibaba-W with HKD 3.320 billion and HKD 3.072 billion, respectively [2] - The stock with the highest net purchase was China National Pharmaceutical Group, with a net purchase of HKD 309 million, and its stock price increased by 10.06% [2] - Alibaba-W experienced the highest net selling amount at HKD 25 million, with its stock price down by 3.83% [2]

Core Insights - On July 9, 2025, the top three companies by trading volume in the southbound Shanghai-Hong Kong Stock Connect were Giant Star Legend (06683), Guotai Junan International (01788), and Alibaba-W (09988) with trading volumes of 10.867 billion, 9.711 billion, and 4.349 billion respectively [1] - In the southbound Shenzhen-Hong Kong Stock Connect, the leading companies were Guotai Junan International (01788), Giant Star Legend (06683), and Alibaba-W (09988) with trading volumes of 3.649 billion, 3.320 billion, and 3.072 billion respectively [1] Southbound Shanghai-Hong Kong Stock Connect - The top active trading companies included: - Giant Star Legend (06683) with a trading amount of 10.867 billion and a net buying amount of +0.235 billion [2] - Guotai Junan International (01788) with a trading amount of 9.711 billion and a net buying amount of +0.175 billion [2] - Alibaba-W (09988) with a trading amount of 4.349 billion and a net buying amount of +1.038 billion [2] - Other notable companies included Tencent Holdings (00700) with a trading amount of 2.644 billion and a net selling amount of -48.5393 million [2] Southbound Shenzhen-Hong Kong Stock Connect - The top active trading companies included: - Guotai Junan International (01788) with a trading amount of 3.649 billion and a net buying amount of +0.631176 billion [2] - Giant Star Legend (06683) with a trading amount of 3.320 billion and a net buying amount of +0.155 billion [2] - Alibaba-W (09988) with a trading amount of 3.072 billion and a net selling amount of -24.5399 million [2] - Other notable companies included Tencent Holdings (00700) with a trading amount of 1.311 billion and a net buying amount of +0.877015 billion [2]

Market Overview - Southbound funds traded approximately 132.6 billion HKD today, accounting for 56.72% of the total turnover of the Hang Seng Index, indicating a short-term high in market share [2] - Despite a pullback in the Hang Seng Index, there are signs of increased investment as southbound funds recorded a net inflow of approximately 9.256 billion HKD, with 6.585 billion HKD from the Shanghai-Hong Kong Stock Connect and 2.672 billion HKD from the Shenzhen-Hong Kong Stock Connect [2] Individual Stock Performance - China Construction Bank (00939.HK) saw a net buy of 1.1 billion HKD, with a slight decline of 0.24% today and a total of 162 million shares added over the past five days [3][4] - Alibaba Group (9988.HK) experienced a net buy of 1.014 billion HKD, but its stock fell by 3.83%, with a reduction of 65.55 million shares over the last five days [3][4] - Meituan (03690.HK) had a net buy of 833 million HKD, with a decline of 2.46% today and an increase of 1.222 million shares over the past five days [3][4] - Xiaomi Group (01810.HK) recorded a net buy of 422 million HKD, with a drop of 2.13% and a reduction of 2.166 million shares in the last five days [3][4] - Legend Holdings (06683.HK) surged by 94.38%, with a net buy of 389 million HKD and an increase of 398,000 shares over the past five days [3][4] - China National Pharmaceutical Group (01177.HK) rose by 10.06%, with a net buy of 309 million HKD and an increase of approximately 10 million shares in the last five days [3][4] Trading Activity - The top active stocks in the southbound trading included Legend Holdings, which had a net inflow of 2.35 billion HKD, and Alibaba, which saw a net outflow of 10.38 billion HKD [5][6] - Over the past month, the total net inflow from southbound trading reached approximately 87.399 billion HKD, with 39.341 billion HKD from the Shanghai Stock Connect and 48.058 billion HKD from the Shenzhen Stock Connect [5]

Core Viewpoint - The recent announcement by President Trump regarding potential high tariffs on copper and pharmaceuticals has led to a decline in Hong Kong's stock market, with the Hang Seng Index falling below 24,000 points, reflecting increased macroeconomic risks and impacting market sentiment [1][4]. Market Performance - The Hang Seng Index closed down 1.06% at 23,892.32 points, with a total trading volume of 233.88 billion HKD. The Hang Seng China Enterprises Index fell 1.28%, while the Hang Seng Tech Index dropped 1.76% [1]. - Major blue-chip stocks experienced significant movements, with Henderson Land Development leading the decline, down 8.64% at 25.9 HKD, while China Biologic Products rose 10.06% to 5.91 HKD [2]. Sector Analysis - The technology sector saw a collective decline, with Alibaba down nearly 4% and Tencent over 1%. The copper sector was negatively impacted by Trump's tariff threats, leading to a drop in copper-related stocks [3][6]. - The innovative drug sector performed well, with Hengrui Medicine surging 15.61% to 69.6 HKD, indicating resilience amid broader market declines [3][4]. Specific Stock Movements - Macau's gaming sector showed strong performance, with Wynn Macau up 6.33% and Melco Resorts up 2.12%, driven by robust gaming revenue growth [4][5]. - Copper stocks faced significant declines, with Luoyang Molybdenum down 4.74% and Jiangxi Copper down 3.46%, reflecting market reactions to tariff announcements [5][6]. Commodity Prices - International gold prices fell below 3,300 USD per ounce, influenced by reduced safe-haven demand amid tariff uncertainties. Analysts expect gold prices to remain volatile within a range of 3,000 to 3,500 USD per ounce [7].

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1]. Group 1: Fund Performance - As of July 9, 2024, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 1.08% and a trading volume of 2.352 billion yuan [1]. - The fund's share volume increased by 419.87% from 3.95 million shares at the end of 2023 to 20.55 million shares by July 8, 2024 [1]. - The fund's size grew by 749.27%, from 378 million yuan at the end of 2023 to 3.209 billion yuan by July 8, 2024 [1]. Group 2: Liquidity and Trading Activity - Over the last 20 trading days, the cumulative trading amount for the ETF reached 42.082 billion yuan, with an average daily trading amount of 2.104 billion yuan [1]. - Since the beginning of the year, the ETF has recorded a total trading amount of 100.143 billion yuan over 124 trading days, averaging 808 million yuan per day [1]. Group 3: Fund Management - The current fund manager, Ma Jun, has managed the Hong Kong Innovative Drug ETF since its inception on January 3, 2024, achieving a return of 56.11% during the management period [1]. Group 4: Top Holdings - The ETF's top holdings include WuXi Biologics (11.47%), BeiGene (10.87%), and Innovent Biologics (9.60%), among others, indicating a focus on leading companies in the innovative drug sector [2]. - The fund's holdings are diversified across several key players in the biotechnology and pharmaceutical industries, with significant positions in companies like China Biologic Products and CSPC Pharmaceutical Group [2].

Market Overview - US President Trump has issued new tariff policy letters to 14 countries, leading to a rebound in Hong Kong stocks, with the Hang Seng Index rising 1.09% to 24,148.07 points, ending a three-day decline [1] - The total trading volume for the day was HKD 213.29 billion, indicating active market participation [1] - The Hong Kong Monetary Authority has withdrawn HKD 59.072 billion in liquidity since June 28, tightening liquidity expectations in the short term [1] Blue Chip Performance - Xinyi Solar (00968) led blue-chip gains, rising 5.43% to HKD 2.91, contributing 1.04 points to the Hang Seng Index [2] - Kuaishou-W (01024) and Chow Tai Fook (01929) also saw significant increases of 5.16% and 4.42%, respectively [2] - However, Orient Overseas International (00316) and China Biologic Products (01177) experienced declines, dragging down the index [2] Sector Highlights - Large tech stocks rebounded, with Kuaishou rising over 5% and Meituan and JD.com both increasing over 2% [3] - Stablecoin concept stocks surged, with Jinyong Investment (01328) skyrocketing 533.17% after announcing a partnership with AnchorX [3] - The Macau gaming sector showed strong performance, with total gaming revenue for the first six days of July reaching MOP 4.3 billion, indicating a robust recovery [6] Solar Industry Insights - The solar sector saw strong gains, with New Special Energy (01799) up 12.65% and GCL-Poly Energy (03800) up 10.81% [5] - Recent government meetings emphasized the need to address low-price competition and improve product quality in the solar industry, suggesting potential for supply-side reforms [5] Gaming Sector Developments - Macau's gaming stocks continued to rise, with Wynn Macau (01128) up 6.4% and MGM China (02282) up 3.29% [6] - Morgan Stanley's report indicated that Macau's gaming revenue is expected to see double-digit year-on-year growth in July, marking a cyclical turning point for the industry [6] New Consumption Trends - New consumption stocks performed well, with brands like Blukoo (00325) and Cha Ba Dao (02555) seeing significant increases [6][7] - Gold stocks also rebounded, with Tongguan Gold (00340) rising 6.37% [7] Stablecoin Regulatory Developments - Jinyong Investment announced a strategic partnership with AnchorX to explore potential collaborations in digital asset management and stablecoin applications [4] - The Hong Kong Monetary Authority is consulting the market on regulatory guidelines for stablecoins, with expectations for a limited number of licenses to be issued [4] Logistics Sector Performance - Jitu Express-W (01519) reached a new high, with a reported 23.5% year-on-year increase in package volume for Q2 2025 [9] - The company achieved a total package volume of 139.9 billion for the first half of 2025, reflecting strong growth in the logistics sector [9] AI and Technology Sector Insights - Hongteng Precision (06088) saw an increase of 8.82%, driven by growing demand for AI-related solutions [10] - The company is expected to benefit from its parent group's resources and the increasing demand for AI computing power [10]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 1.44% on July 7, with a trading volume of 1.402 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 4, 2024, the fund's latest share count was 1.995 billion shares, with a total size of 3.203 billion yuan, reflecting a 404.69% increase in shares and a 747.72% increase in size year-to-date [1] Group 2 - The fund's liquidity showed a cumulative trading amount of 44.415 billion yuan over the last 20 trading days, with an average daily trading amount of 2.221 billion yuan [1] - Year-to-date, the cumulative trading amount reached 96.310 billion yuan over 122 trading days, with an average daily trading amount of 789 million yuan [1] - The current fund manager, Ma Jun, has managed the fund since its inception, achieving a return of 60.51% during the tenure [1] Group 3 - The top holdings of the Hong Kong Innovative Drug ETF include WuXi Biologics (11.47%), BeiGene (10.87%), and Innovent Biologics (9.60%), among others [2] - The fund's holdings are diversified across various companies in the innovative drug sector, with significant investments in both domestic and international firms [2]